My Cart [ 0 ]
Home > Antibodies > Research-Grade Biosimilars > Tanezumab Biosimilar, NGF Monoclonal Antibody

Tanezumab Biosimilar, NGF Monoclonal Antibody

Nerve Growth Factor

Catalog No. Product Name Size List Price (US$) Quantity
C110P Tanezumab Biosimilar, Human NGF Monoclonal Antibody 1 mg 175.00
C110P Tanezumab Biosimilar, Human NGF Monoclonal Antibody 5 mg 480.00
C110P Tanezumab Biosimilar, Human NGF Monoclonal Antibody 20 mg 1200.00
C110P.NA Tanezumab Biosimilar, N297A Mutant 1 mg 650.00
C110P.LA Tanezumab Biosimilar, L234A L235A P329G (LALAPG) Fc Silent Mutant 1 mg 650.00
Description

C110P: Tanezumab Biosimilar, NGF Monoclonal Antibody

Recombinant Humanized IgG2 Monoclonal Antibody.
Isotype: Human IgG2 kappa.
Source: The anti-human NGF monoclonal antibody tanezumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade tanezumab biosimilar specifically binds to the NGF protein.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by tanezumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The research grade tanezumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Background

What is tanezumab biosimilar research grade? Tanezumab is a humanized IgG2-kappa monoclonal antibody against nerve growth factor (NGF) as a treatment for pain via a novel mechanisms different from conventional pain-killer drugs. NGF levels increase in the body as a result of injury, inflammation or in chronic pain states. Tanezumab selectively targets, binds to, and inhibits NGF. Tanezumab acts in the periphery in a different manner than opioids and other analgesics, including nonsteroidal anti-inflammatory drugs (NSAIDs), and in studies to date, tanezumab has not demonstrated a risk of addiction, misuse or dependence. Tanezumab biosimilar uses the same protein sequences as the therapeutic antibody tanezumab.

Syd Labs provides the following research grade antibody biosimilars used in ADCs:
Tusamitamab biosimilar, research grade, anti-human CEACAM5 monoclonal antibody
Rovalpituzumab biosimilar, research grade, anti-human DLL3 monoclonal antibody
Trastuzumab biosimilar, research grade, anti-human HER2 monoclonal antibody
Cofetuzumab biosimilar, research grade, anti-human PTK7 monoclonal antibody
Ifinatamab biosimilar, research grade, anti-human B7-H3 (CD276) monoclonal antibody
Sacituzumab biosimilar, research grade, anti-human Trop-2 monoclonal antibody
Gemtuzumab biosimilar, research grade, anti-human CD33 monoclonal antibody
Polatuzumab biosimilar, research grade, anti-human CD79B monoclonal antibody
Cetuximab biosimilar, research grade, anti-human EGFR monoclonal antibody

Related Links

See our Privacy Policy